LifeTech Capital Updates Research Coverage of Biomoda
06.28.2010 — 8:00 am
LifeTech Capital, a division of Aurora Capital LLC, has updated its independent research coverage on Biomoda, Inc. (OTC BB: BMOD), a cancer diagnostics company working on accurate, inexpensive and noninvasive tests for the early detection of cancer. Noting that Biomoda has completed patient enrollment and sample collection in its pilot study for a diagnostic assay for early-stage lung cancer, LifeTech rates Biomoda a “Strong Speculative Buy” with a 12- to 18-month price target of $1.00 per share.
LifeTech Capital is an investment bank that specializes in the biotechnology and medical technology industries. The report, which was authored by Stephen M. Dunn, Senior Managing Director, Research and William D. Dawson, Senior Vice President, Research for LifeTech Capital, is available online at www.lifetechcapital.com/reports.htm.
Biomoda does not endorse the reports, projections or statements of any analyst. Please be aware that LifeTech’s report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions by LifeTech analysts at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements.